ArticleJournal of robotic surgery2026
Robot-assisted versus open surgery for multiple ipsilateral renal tumors: a multicenter matched cohort study (UroCCR-60).
Article in Journal of robotic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03293563 (UroCCR Database), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
UroCCR Database: French Research Network for Kidney Cancer (National Multidisciplinary Clinical and Biological Database on Kidney Cancer)
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with multiple ipsilateral renal tumors face an increased risk of recurrence, making nephron-sparing surgery (NSS) essential to preserve renal function. Due to their technical complexity, these procedures have traditionally been performed via open partial nephrectomy (OPN). This study aimed to compare perioperative, functional, and oncologic outcomes of robot-assisted partial nephrectomy (RAPN) versus OPN in this challenging setting. We conducted a retrospective analysis of prospectively collected data from 20 centers of the French national kidney cancer research network UroCCR (NCT03293563; CNIL DR-2022-091). The primary endpoint was perioperative morbidity, assessed using the Clavien–Dindo classification. Secondary outcomes included Trifecta achievement, renal functional outcomes (pre- and 3-month postoperative eGFR, new-onset CKD, and AKI), and oncologic outcomes (disease-free survival [DFS], and overall survival [OS]). Overall, 212 patients underwent NSS for multiple ipsilateral renal tumors between June 2007 and July 2025 (146 RAPN, 66 OPN). After 1:1 matching for BMI, ASA score, and indication for NSS, 132 patients were analyzed (66 per group). RAPN was associated with shorter hospitalization (3.2 vs. 7.7 days, p < 0.001), fewer complications (6.1% vs. 21.2%, p = 0.02), and less frequent main renal artery clamping (51.5% vs. 86.4%, p < 0.001), despite longer operative and clamping times. Trifecta rates (50.8% vs. 61.9%, p = 0.29) and renal function at 3 months were comparable. At a median follow-up of 30.7 months, DFS and OS did not differ significantly between groups (p = 0.69). RAPN is a safe and effective alternative to OPN for multiple ipsilateral renal tumors, providing comparable oncologic and functional outcomes with reduced morbidity.
Indexed as
Identifiers
41801584What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.